Based on the Biora Therapeutics Inc stock forecast from 0 analysts, the average analyst target price for Biora Therapeutics Inc is not available over the next 12 months. Biora Therapeutics Inc’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Biora Therapeutics Inc is Bearish, which is based on 2 positive signals and 5 negative signals. At the last closing, Biora Therapeutics Inc’s stock price was USD 0.22. Biora Therapeutics Inc’s stock price has changed by +0.00% over the past week, -61.55% over the past month and -98.25% over the last year.
No recent analyst target price found for Biora Therapeutics Inc
No recent average analyst rating found for Biora Therapeutics Inc
Company Overview Biora Therapeutics Inc
Biora Therapeutics, Inc., a clinical-stage biotechnology company, engages in developing oral biotherapeutics in the United States. The company offers NaviCap, a targeted oral delivery platform for delivery of therapeutics in the gastrointestinal tract to enhance the treatment of inflammatory bowel diseases; and BioJet, a systemic oral delivery platform designs to replace injection with needle-free, oral delivery of large molecules for management of chronic diseases. The company was formerly known as Progenity, Inc. and changed its name to Biora Therapeutics, Inc. in April 2022 to reflect its focus on its therapeutics pipeline. Biora Therapeutics, Inc. was founded in 2010 and is headquartered in San Diego, California. On December 27, 2024, Biora Therapeutics, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware. Read Less
Biora Therapeutics, Inc., a clinical-stage biotechnology company, engages in developing oral biotherapeutics in the United States. The company offers NaviCap, a targeted oral delivery platform for delivery of therapeutics in the gastrointestinal tract to enhance the treatment of ...Read More
Frequently Asked Questions About Biora Therapeutics Inc (BIOR) Stock
Stock Target Advisor's fundamental analysis for Biora Therapeutics Inc's stock is Bearish.
Unfortunately we do not have enough data on BIOR's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on BIOR's stock to indicate what its average analyst target is.
BIOR stock's Price/Earning ratio is 0.61.
Our analysis grades BIOR stock's Price / Earning ratio at C. This means that BIOR stock's Price/Earning ratio is above 27% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this BIOR may be undervalued for its sector.
The last closing price of BIOR's stock was USD 0.22.
The most recent market capitalization for BIOR is USD 0.99M.
Unfortunately we do not have enough analyst data on BIOR's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Biora Therapeutics Inc's stock.
As per our most recent records Biora Therapeutics Inc has 58 Employees.
Biora Therapeutics Inc's registered address is 4330 La Jolla Village Drive, San Diego, CA, United States, 92122.
You can get more information about it from Biora Therapeutics Inc's website at https://www.bioratherapeutics.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Superior capital utilization
The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.
Superior Earnings Growth
This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.
What not to like
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Low market capitalization
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Low Revenue Growth
This stock has shown below median revenue growth in the previous 5 years compared to its sector
Frequently Asked Questions About Biora Therapeutics Inc (BIOR) Stock
Stock Target Advisor's fundamental analysis for Biora Therapeutics Inc's stock is Bearish.
Unfortunately we do not have enough data on BIOR's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on BIOR's stock to indicate what its average analyst target is.
BIOR stock's Price/Earning ratio is 0.61.
Our analysis grades BIOR stock's Price / Earning ratio at C. This means that BIOR stock's Price/Earning ratio is above 27% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this BIOR may be undervalued for its sector.
The last closing price of BIOR's stock was USD 0.22.
The most recent market capitalization for BIOR is USD 0.99M.
Unfortunately we do not have enough analyst data on BIOR's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Biora Therapeutics Inc's stock.
As per our most recent records Biora Therapeutics Inc has 58 Employees.
Biora Therapeutics Inc's registered address is 4330 La Jolla Village Drive, San Diego, CA, United States, 92122.
You can get more information about it from Biora Therapeutics Inc's website at https://www.bioratherapeutics.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for BIOR !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
